CalciMedica, Inc. CALC
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
CalciMedica, Inc. (CALC) is a healthcare company listed in the US with a market value of about $8M.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.3, a 5-year average ROIC of -268%.
About CalciMedica
CalciMedica is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. It was profitable in 0 of the last 7 years in our data. Its share count rose by 18152% over three years (dilution for shareholders).
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$30M | -$14M | -$34M | -$8M | -$36M | -$28M | -$37M |
| Free cash flow | -$21M | -$21M | -$26M | -$12M | -$32M | -$33M | -$32M |
| EPS (diluted) | $-1.97 | $-1.22 | $-7.66 | $-111.16 | $-441.57 | $-1371.74 | $-8729.49 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | — | -168.0% | -368.8% | — | — | -24.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is CalciMedica’s P/E ratio?
About 0.3, based on the last twelve months of diluted earnings per share.
Does CalciMedica pay a dividend?
Not currently.
Is CalciMedica a good stock to buy?
We do not give buy or sell advice. CalciMedica scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.